Dr. Tanja Obradovic

Dr. Obradovic has over 25 years of experience in life sciences focusing on pharmaceutical drug development in oncology. She has extensive experience in oncology clinical development, medical affairs strategy and cancer drug development business aspects gained from holding increasing senior positions in pharmaceutical companies. At Merck she significantly contributed to Keytruda’s development and life cycle management across various tumor indications for over 10 years followed by her work at Takeda on novel immune and cell therapies. Most recently she was Vice President at ICON, one of the largest CROs, leading and shaping oncology drug development solutions and medical affairs strategy. Dr. Obradovic’s clinical development work on Keytruda and numerous other novel therapies (antibodies, small molecules, antibody drug conjugates (ADCs), cell and gene therapy, etc.) lead to successful regulatory outcomes and market access and has been showcased at scientific meetings as an invited speaker, reviewer and expert panelist. Prior to joining the pharmaceutical industry, she was Research Assistant Professor at Temple University pioneering immuno-oncology research. Dr. Obradovic is currently sought after as an expert advisor for Biotech companies and the investment community.